Juan Francisco Vázquez Costa obtained his degree in Medicine from the University of Valencia in 2005. In 2005 and 2006, he conducted a research placement in the Department of Child and Youth Psychiatry at the University of Freiburg. From 2008 to 2012, he completed his neurology residency at the Hospital la Fe, with a three-month training stay in the dementia department of the Massachusetts General Hospital and in the Neuroimaging Research Martinos Center (Boston, USA). He then joined the Research Group in Neuromuscular Pathology and Ataxias (GIPNMA) of the Research Foundation of Hospital la Fe and a national group for the study of rare diseases (CIBERER). There, he specialized in the diagnosis and treatment of rare neuromuscular diseases, particularly motor neuron diseases, after obtaining various competitive fellowships. In February 2019, he completed his doctoral thesis with a project of biomarkers and genetics in ALS. During these years he participated in 17 research projects (in many of them as principal investigator) and actively collaborated with researchers from several research institutes and universities. He has also participated as investigator in over 20 clinical trials in dementias and neuromuscular diseases and as principal investigator in two clinical trials in ALS. Juan Francisco Vázquez Costa has published 41 articles in indexed peer reviewed journals, most of them on ALS, and several book chapters. He has also developed a software together with the Polytechnic University of Valencia that is accepted and published in the Patent Bank of the Ministry of Sustainable Economy and Productive Sectors. Since January 2020 he continues working in the GIPNMA with a contract of excellence Juan Rodés of the Ministry of Health for a project on ALS.
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.